



**UPDATED AND REVISED**

**March 2016**

**Oncology – Molecular and Cellular Tumor Markers**

**“Next Generation” Sequencing (NGS) guidelines for somatic genetic variant detection**

The following describes requirements for the development of procedures and the establishment of performance (validation) of assays for the detection of somatic genetic variants by Next Generation/massively parallel sequencing (NGS) technologies. These requirements should be used in conjunction with and not in lieu of the existing molecular oncology guidelines (available at <http://www.wadsworth.org/regulatory/clep/clinical-labs/obtain-permit/test-approval/submission-checklists>). Overall, clinical validation of NGS assays follows the same basic principles for validating most other complex molecular diagnostic procedures. It is anticipated that these guidelines will evolve as the field matures and gains experience. Please make sure you use the most up-to-date version of these guidelines. Issues that must specifically be addressed include:

**SOP:**

- must include step-by-step description of all steps involved, from template to library preparation to data analysis and interpretation
- must include indication for the specific procedure(s) used for confirmation testing, including criteria for when confirmation must be performed

**QC:**

- Quality of the base scoring must meet a minimum of Q20 or equivalent per base.
- Establish minimum criteria for depth and uniformity of coverage, i.e. number of reads, across all target areas. A minimum average of 500 reads or greater is **strongly** recommended.
- Define the minimum coverage required for a target area (such as amplicon, exon) below which you cannot confidently define the area’s mutation status; the minimum coverage required may be different for mutated vs. unmutated calls.
- Define the minimum percentage of variant reads in a background of normal reads required to call a variant ‘detected’ at your established confidence and sensitivity.
- Define maximal allowable strand bias (if applicable).
- New reagent lots require verification/confirmation of the analytical sensitivity to ensure that low positives will not be missed by new lots of reagents. This applies to all critical reagents and includes depth and uniformity of coverage to detect possible target area drop out.
- All QC metrics must be followed and documented over time to verify that there is no decrease in performance.
- All software updates that affect key parameters, such as base calling, alignment, etc., must be revalidated using data from at least 3-5 previously analyzed runs to verify that all genetic variants are still detected with the same analytical sensitivity as previously determined. This validation must also

verify that coverage depth and variant read prevalence is not significantly different between the two software versions. The revalidation process must be clearly described in the SOP.

### **Controls:**

- A **No Template Control** (NTC) must be included in all amplification steps to verify that there is no contamination across samples and reagents. This control can be analyzed by any suitable method before proceeding to the actual sequencing.
- During the initial validation and periodically thereafter, a **negative control**, such as DNA from a HapMap cell line, e.g. NA12878 and/or NA19240, should be included to verify analytic accuracy and specificity for the detection of variants.
- A **positive/sensitivity control** should be included in each run. We suggest this control be an individually barcoded low positive DNA sample containing multiple known variants of each kind to be detected near the sensitivity of the assay, to verify that low percentage variants can be identified consistently. A defined rotation schedule should be employed if not all variants in all target areas can be incorporated in a single control sample.

### **Reports:**

- Reports should include all detected somatic variants, whether targeted or incidental, and whether of known or unknown clinical significance, in a manner clearly identifying each variant's significance.  
  
Our intent in including all detected somatic variants on the report is to absolve the lab from having to potentially report these out at a later time. If the oncologist has all the NGS data then he/she would not have to contact the performing laboratory further in case new information from a clinical trial emerges. However, we would not object to the inclusion of a statement such as *“This test is designed to detect x, y and z...in genes a,b and c... However, variants other than the ones listed above may also have been detected. If interested, these can be released upon request”*.
- Variants can only be reported if they are confirmed or if the assay has been fully validated and confirmation is no longer necessary (see below).
- Incidental findings of possible germline variants: we suggest you include these on your report separately and alert the treating physician to their potential clinical relevance.
- Reports must include statement(s) that identify the limitations of the assay, including for which target area(s) the assay lacked sufficient coverage to confidently determine mutational status.

### **Validation:**

- Performance characteristics must be **established and validated separately** for each type of variant the assay is intended to detect, e.g. single nucleotide variants (SNVs), indels, copy number variants (CNVs) and structural variants.
- Performance characteristics for each sample type (e.g. FFPE, FF, WB, BM, FNA) must be established and validated, along with demonstration of quality sequences for all target areas without sample type bias.
- **Minimum** data required to establish key performance characteristics (please include the prevalence, i.e. number of total, normal and variant reads of each detected variant for all studies; a table and graph (e.g. histogram) of read depths for each target area is recommended):

- **Accuracy:** Sequence a minimum of 3 well-characterized reference samples (e.g. HapMap DNA NA12878, NA19240, or Genome in a Bottle) to determine a robust laboratory specific error rate across all target areas (specificity). This error rate is expected to be < 2%.
- **Initial validation:** Must include a minimum of 50 patient samples comprising specimens of all intended sample and tumor types. However, if FFPE is included then  $\geq 75\%$  of samples should be derived from FFPE. This is to ensure that the assay is robust when utilizing the most degraded source of sample input. These samples must contain a representative distribution of reportable variants across all target areas (including GC-rich sequences), and must be confirmed by an independent reference method. The independent reference method cannot utilize the same technology as the NGS platform unless it is performed in a different lab.
- **Full validation:** 10 positive samples for each type of intended variant in each target area must be sequenced and confirmed. For reported variants with clinical significance identified during clinical runs that have not yet been fully validated ongoing validation, i.e. confirmation by an independent reference method, must be performed for each distinct target area until such a time that at least 10 positive samples per type of intended variant have been verified using the independent reference method.
  - SNVs: Confirmation can be ceased once a **minimum of 20 target areas** have been fully validated/confirmed with accuracy greater than or equal to your established specificity. This requirement is independent of the size of the panel; panels smaller than 20 genes cannot meet this 20 target area requirement and thus all genes must be fully validated. Incorporation of additional target areas to a panel will require reassessment of specificity within those additional target areas. There should be particular attention paid to regions of the target areas with high probability of error (e.g. GC rich regions).
  - Indels: Confirmation can be ceased once a **minimum of 20 target areas** have been fully validated/confirmed with accuracy greater than or equal to your established specificity. This requirement is independent of the size of the panel; panels smaller than 20 genes cannot meet this 20 target area requirement and thus all genes must be fully validated. Incorporation of additional target areas to a panel will require reassessment of specificity within those additional target areas. There should be particular attention paid to regions of the target areas with high probability of error (e.g. homopolymer or repetitive regions).
  - CNVs must always be fully validated (on-going validation is acceptable until 10 CNVs have been confirmed per gene).
  - Translocations will require a minimum of 3 confirmations per gene fusion partner **targeted** by the assay. For example, if the assay targets ALK then you need only confirm 3 positive ALK rearrangements to fully validate **any** rearrangements that contain the ALK gene as one of the fusion partners. Confirmation accuracy should be  $\geq 95\%$  for each targeted gene.
  - Any novel variant type detected by your assay must be confirmed (e.g. an indel or translocation in KRAS) even if discovered in a fully validated target area if it is going to be reported as potentially actionable.
- **Precision** (within run): for each type of variant a minimum of 3 positive patient samples containing variants near the stated sensitivity of the assay must be analyzed in triplicate in the same run using different barcodes.
- **Reproducibility** (between run): for each type of variant a minimum of 3 positive patient samples containing variants near the stated sensitivity of the assay must be analyzed in three separate runs

using different barcodes (from the original DNA through sequencing and data analysis) on different days by 2 different technologists (if possible).

- If multiplexing samples with distinct barcodes, it must be verified that there is no cross talk between samples and barcodes and that the combinations of patients/barcodes in a run provides reproducible results for all target areas and types of variants independent of which patient/barcode combination is used.
  - **Analytical sensitivity:** Establish the analytical sensitivity of the assay for each type of variant detected by the assay. This can initially be established with defined mixtures of cell line DNAs (not plasmids), but needs to be verified with 3-5 patient samples.
- 
- Demonstrate the accuracy and reproducibility of the bioinformatics process, both for the detection of all types of variants and (if applicable) the identification and sorting of individually barcoded and multiplexed patient samples.
  - The initial validation studies should be done with a single version of all analyses software.